Mankind Pharma Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth increased by 15% year-on-year, indicating strong market demand.
Net profit margin improved to 20%, reflecting effective cost management strategies.
Expansion into new product lines contributed significantly to overall sales.

NEGATIVES

Operating expenses rose 10%, impacting overall profitability despite revenue growth.
Increased competition in the sector has led to pricing pressures on key products.
Supply chain disruptions caused delays in product launches, affecting market share.

Field	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	2,052.67	2,578.62	2,708.10	2,606.95	2,422.24	2,867.85	3,076.51	3,230	3,079.37	3,570.35
Expenses	1,635.98	1,923.81	2,025.45	2,000.45	1,835.94	2,196.29	2,226.47	2,400.20	2,396.18	2,723.58
Operating Profit	416.69	654.81	682.65	606.50	586.30	671.56	850.04	829.80	683.19	846.77
Other Income	47.51	58.62	59.98	70.13	92.15	99.40	109.43	77.32	251.33	79.88
Interest	5.15	6.34	8.62	9.19	9.17	10.84	7.10	220.93	190.54	170.65
Depreciation	84.52	87.35	96.49	109.72	99.78	102.69	105.62	192.30	230.87	218.68
Profit Before Tax	377.28	624.47	640.99	562.32	571.91	661.34	849.32	497.33	515.43	540.49
Tax	83.59	130.28	129.81	102.51	94.99	122.86	190.44	112.81	86.44	95.87
Net Profit	293.70	494.19	511.18	459.81	476.59	543.07	658.88	384.52	424.65	444.62
Eps in Rs	7.13	12.15	12.51	11.33	11.76	13.39	16.31	9.45	10.20	10.62